Update on the role of endovesical chemotherapy in nonmuscle-invasive bladder cancer

Actas Urol Esp (Engl Ed). 2018 Mar;42(2):73-76. doi: 10.1016/j.acuro.2017.09.006. Epub 2017 Nov 10.
[Article in English, Spanish]
No abstract available

Publication types

  • Editorial

MeSH terms

  • Administration, Intravesical
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carcinoma, Transitional Cell / drug therapy*
  • Carcinoma, Transitional Cell / epidemiology
  • Carcinoma, Transitional Cell / pathology
  • Carcinoma, Transitional Cell / surgery
  • Combined Modality Therapy
  • Doxorubicin / administration & dosage
  • Doxorubicin / adverse effects
  • Epirubicin / administration & dosage
  • Epirubicin / adverse effects
  • Humans
  • Mitomycin / administration & dosage
  • Mitomycin / adverse effects
  • Neoplasm Invasiveness
  • Neoplasm Recurrence, Local / prevention & control
  • Practice Guidelines as Topic
  • Urinary Bladder Neoplasms / drug therapy*
  • Urinary Bladder Neoplasms / epidemiology
  • Urinary Bladder Neoplasms / pathology
  • Urinary Bladder Neoplasms / surgery

Substances

  • Epirubicin
  • Mitomycin
  • Doxorubicin